Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tirzepatide plans start as low as $199 monthly
Dive Brief: An experimental obesity shot Pfizer got through a buyout of Metsera helped enrollees in a mid-stage trial lose significantly more weight than a placebo, spurring up to an 11% reduction over 28 weeks using a regimen that switched from a weekly to monthly dose after 12 weeks
Log in View All Plans To read the rest of this story subscribe to STAT+
This educational protocol presents a once-daily subcutaneous dosing framework and uses a practical dilution method designed to support accurate insulin-syringe measurement in research and educational settings
US$ 28.11
US$ 26.74
US$ 24.23
